A
Anette S. B. Wolff
Researcher at University of Bergen
Publications - 58
Citations - 2744
Anette S. B. Wolff is an academic researcher from University of Bergen. The author has contributed to research in topics: Autoantibody & Autoimmune regulator. The author has an hindex of 23, co-authored 53 publications receiving 2295 citations. Previous affiliations of Anette S. B. Wolff include Haukeland University Hospital & National Institute for Biological Standards and Control.
Papers
More filters
Journal ArticleDOI
Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry
Martina M. Erichsen,Kristian Løvås,Kristian Løvås,Beate Skinningsrud,Beate Skinningsrud,Anette S. B. Wolff,Dag E. Undlien,Dag E. Undlien,Johan Svartberg,Johan Svartberg,Kristian J. Fougner,Tore Julsrud Berg,Jens Bollerslev,Jens Bollerslev,Bjarne Mella,Joyce Carlson,Henry A. Erlich,Eystein S. Husebye,Eystein S. Husebye +18 more
TL;DR: Both anti-21-hydroxylase antibodies and HLA class II can be clinically relevant predictors of AD, and treatment modalities that improve HRQoL are needed.
Journal ArticleDOI
AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies
Steffen Meyer,Martin Woodward,Christina Hertel,Philip Vlaicu,Yasmin Haque,Jaanika Kärner,Annalisa Macagno,Shimobi Onuoha,Dmytro Fishman,Hedi Peterson,Kaja Metsküla,Raivo Uibo,Kirsi Jäntti,Kati Hokynar,Anette S. B. Wolff,Antonella Meloni,Nicolas Kluger,Eystein S. Husebye,Katarina Trebušak Podkrajšek,Tadej Battelino,Nina Bratanic,Aleksandr Peet,Kai Krohn,Annamari Ranki,Pärt Peterson,Kai Kisand,Adrian Hayday +26 more
TL;DR: It is shown that most APS1/APECED patients displayed B cell autoreactivity toward unique sets of approximately 100 self-proteins, and naturally occurring human autoantibodies may actively limit disease and be of therapeutic utility.
Journal ArticleDOI
Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene.
Anette S. B. Wolff,Martina M. Erichsen,Anthony Meager,Ng’weina Francis Magitta,Ng’weina Francis Magitta,Anne Grethe Myhre,Jens Bollerslev,Kristian J. Fougner,Kari Lima,Per M. Knappskog,Per M. Knappskog,Eystein S. Husebye,Eystein S. Husebye +12 more
TL;DR: The clinical features and the AIRE mutations are more diverse in the Norwegian population than previously thought, and some patients with APS I clinically resemble those from Finland and other European countries, but some have milder phenotypes.
Journal ArticleDOI
Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases.
Bergithe E. Oftedal,Alexander Hellesen,Alexander Hellesen,Martina M. Erichsen,Eirik Bratland,Ayelet Vardi,Jaakko Perheentupa,E. Helen Kemp,Torunn Fiskerstrand,Torunn Fiskerstrand,Marte K. Viken,Anthony P. Weetman,Sarel J. Fleishman,Siddharth Banka,Siddharth Banka,William G. Newman,William G. Newman,W.A.C. Sewell,Leila S. Sozaeva,Tetyana Zayats,Kristoffer Haugarvoll,Elizaveta Orlova,Jan Haavik,Stefan Johansson,Stefan Johansson,Per M. Knappskog,Per M. Knappskog,Kristian Løvås,Kristian Løvås,Anette S. B. Wolff,Jakub Abramson,Eystein S. Husebye,Eystein S. Husebye +32 more
TL;DR: It is shown that disease-causing mutations in the AIRE locus are more common than previously appreciated and cause more variable autoimmune phenotypes and that the PHD1 dominant mutants were found with relatively high frequency in mixed populations.
Journal ArticleDOI
Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I
Antonella Meloni,Maria Furcas,Filomena Cetani,Claudio Marcocci,Alberto Falorni,Roberto Perniola,Mikulas Pura,Anette S. B. Wolff,Eystein S. Husebye,Desa Lilic,Kelli R. Ryan,Andrew R. Gennery,Andrew J. Cant,Mario Abinun,Gavin P. Spickett,Peter D. Arkwright,David W. Denning,Colm Costigan,Maria Dominguez,Vivienne McConnell,Nick Willcox,Anthony Meager +21 more
TL;DR: Precocious persistent antibodies found in patients with thymoma and/or myasthenia gravis show 98% or higher sensitivity and APS-I specificity and are thus a simpler diagnostic option than detecting AIRE mutations.